SAREPTA THERAPEUTICS INC (NASDAQ: SRPT)

SAREPTA THERAPEUTICS INC

NASDAQ: SRPT (Sarepta Therapeutics, Inc.)

Last update: 8 hours ago

18.21

0.02 (0.08%)

Add to watchlist

Previous Close	18.20
Open	18.44
Volume	1,934,826
Avg. Volume (3M)	5,369,134
Market Cap	1,789,624,064

Price / Earnings (Forward)	9.84
Price / Sales	0.890
Price / Book	1.56

52 Weeks Range	16.88 (-7%) — 154.90 (750%)
Earnings Date	6 Aug 2025

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Bearish	Bearish
	Biotechnology (Global)	Bearish	Bearish
Stock	Sarepta Therapeutics, Inc.	Bearish	Bearish

AIStockmoo Score

0.6

Analyst Consensus	-0.5
Insider Activity	NA
Price Volatility	3.0
Technical Moving Averages	2.5
Technical Oscillators	-2.5
Average	0.63

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
SRPT	2 B	-	-	1.56
EXEL	12 B	-	19.94	5.51
CORT	8 B	-	62.84	10.75
HALO	6 B	-	13.87	13.34
TGTX	6 B	-	144.40	24.96
ACAD	4 B	-	15.50	4.84

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Sector	Healthcare
Industry	Biotechnology
Investment Style	Small Growth
% Held by Insiders	4.42%
% Held by Institutions	96.33%

Ownership

Name	Date	Shares Held
Avoro Capital Advisors Llc	31 Mar 2025	2,674,835

52 Weeks Range	16.88 (-7%) — 154.90 (750%)
Price Target Range	10.00 (-45%) — 98.00 (438%)
High	98.00 (Guggenheim, 438.17%)	Buy
Median	45.00 (147.12%)
Low	10.00 (HC Wainwright & Co., -45.09%)	Sell
Average	50.63 (178.03%)
Total	11 Buy, 7 Hold, 1 Sell
Avg. Price @ Call	25.55

Firm	Date	Target Price	Call	Price @ Call
HC Wainwright & Co.	25 Jun 2025	10.00 (-45.09%)	Sell	17.46
HC Wainwright & Co.	16 Jun 2025	10.00 (-45.09%)	Sell	20.94
Oppenheimer	20 Jun 2025	45.00 (147.12%)	Buy	20.08
Oppenheimer	07 May 2025	123.00 (575.45%)	Buy	36.72
Mizuho	18 Jun 2025	40.00 (119.66%)	Buy	20.77
Baird	17 Jun 2025	30.00 (64.74%)	Buy	21.56
Barclays	17 Jun 2025	29.00 (59.25%)	Buy	21.56
Deutsche Bank	17 Jun 2025	25.00 (37.29%)	Hold	21.56
Goldman Sachs	17 Jun 2025	29.00 (59.25%)	Hold	21.56
Goldman Sachs	07 May 2025	100.00 (449.15%)	Buy	36.72
Morgan Stanley	17 Jun 2025	40.00 (119.66%)	Hold	21.56
Morgan Stanley	07 May 2025	113.00 (520.54%)	Buy	36.72
Wells Fargo	17 Jun 2025	75.00 (311.86%)	Buy	21.56
Wells Fargo	08 May 2025	100.00 (449.15%)	Buy	36.52
B of A Securities	16 Jun 2025	28.00 (53.76%)	Hold	20.94
BMO Capital	16 Jun 2025	70.00 (284.40%)	Hold	20.94
Jefferies	16 Jun 2025	54.00 (196.54%)	Buy	20.94
Needham	16 Jun 2025	50.00 (174.57%)	Buy	20.94
Needham	07 May 2025	125.00 (586.44%)	Buy	36.72
Piper Sandler	16 Jun 2025	36.00 (97.69%)	Hold	20.94
Piper Sandler	07 May 2025	70.00 (284.40%)	Buy	36.72
Scotiabank	06 Jun 2025	80.00 (339.32%)	Buy	43.01
JP Morgan	20 May 2025	84.00 (361.29%)	Buy	39.99
Cantor Fitzgerald	07 May 2025	81.00 (344.81%)	Buy	36.72
Guggenheim	07 May 2025	98.00 (438.17%)	Buy	36.72
RBC Capital	07 May 2025	58.00 (218.51%)	Hold	36.72
Show more

No data within this time range.

Date	Type	Details
26 Jun 2025	Announcement	Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Sarepta Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of August 25, 2025
15 Jun 2025	Announcement	Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
04 Jun 2025	Announcement	U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
21 May 2025	Announcement	Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
16 May 2025	Announcement	Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
16 May 2025	Announcement	Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
13 May 2025	Announcement	Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
08 May 2025	Announcement	Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
06 May 2025	Announcement	Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
22 Apr 2025	Announcement	Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
15 Apr 2025	Announcement	Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
04 Apr 2025	Announcement	Sarepta Therapeutics Provides Update on ELEVIDYS
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	-11.12%
Operating Margin (TTM)	-40.33%
Diluted EPS (TTM)	-2.64
Quarterly Revenue Growth (YOY)	80.20%
Quarterly Earnings Growth (YOY)	248.40%

Total Debt/Equity (MRQ)	118.73%
Current Ratio (MRQ)	4.02
Operating Cash Flow (TTM)	-547.15 M
Levered Free Cash Flow (TTM)	-741.26 M

Return on Assets (TTM)	-2.19%
Return on Equity (TTM)	-23.61%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)